Biblio

Export 380 results:
[ Author(Desc)] Title Type Year
Filters: First Letter Of Keyword is R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
P. S. Aisen, Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., Hendrix, S. B., Grundman, M., Schneider, L. S., Schindler, R. J., Salmon, E., Potter, W. Z., Thomas, R. G., Salmon, D., Donohue, M., Bednar, M. M., Touchon, J., and Vellas, B., “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
M. L. Alosco, Duskin, J., Besser, L. M., Martin, B., Chaisson, C. E., Gunstad, J., Kowall, N. W., McKee, A. C., Stern, R. A., and Tripodis, Y., “Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set.”, J Alzheimers Dis, vol. 57, no. 3, pp. 953-968, 2017.
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
E. L. Ashby, Miners, J. S., Kehoe, P. G., and Love, S., “Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1191-203, 2016.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
B
N. Bagheri, Wangdi, K., Cherbuin, N., and Anstey, K. J., “General Practice Clinical Data Help Identify Dementia Hotspots: A Novel Geospatial Analysis Approach.”, J Alzheimers Dis, vol. 61, no. 1, pp. 125-134, 2018.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
M. Barbera, Mangialasche, F., Jongstra, S., Guillemont, J., Ngandu, T., Beishuizen, C., Coley, N., Brayne, C., Andrieu, S., Richard, E., Soininen, H., and Kivipelto, M., “Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial.”, J Alzheimers Dis, vol. 62, no. 2, pp. 649-663, 2018.
F. Barocco, Spallazzi, M., Concari, L., Gardini, S., Pelosi, A., and Caffarra, P., “The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.”, J Alzheimers Dis, vol. 57, no. 3, pp. 775-786, 2017.
R. Beardmore, Hou, R., Darekar, A., Holmes, C., and Boche, D., “The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review.”, J Alzheimers Dis, vol. 83, no. 1, pp. 5-22, 2021.
A. Belkacemi and Ramassamy, C., “Anthocyanins Protect SK-N-SH Cells Against Acrolein-Induced Toxicity by Preserving the Cellular Redox State.”, J Alzheimers Dis, vol. 50, no. 4, pp. 981-98, 2016.
J. Benito-León, Contador, I., Mitchell, A. J., Domingo-Santos, Á., and Bermejo-Pareja, F., “Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES).”, J Alzheimers Dis, vol. 51, no. 2, pp. 533-44, 2016.
G. Berge, Lauridsen, C., Sando, S. Botne, Holder, D. Joseph, Møller, I., Aasly, J. Olav, Bråthen, G., Savage, M. Josephine, and White, L. Rosemary, “Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.”, J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
M. Berger, Cooter, M., Roesler, A. S., Chung, S., Park, J., Modliszewski, J. L., VanDusen, K. W., J Thompson, W., Moseley, A., Devinney, M. J., Smani, S., Hall, A., Cai, V., Browndyke, J. N., Lutz, M. W., and Corcoran, D. L., “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
D. Bergeron, Beauregard, J. - M., Guimond, J., Fortin, M. - P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., and Laforce, R., “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
D. Bergeron, Beauregard, J. - M., Guimond, J., Fortin, M. - P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., and Laforce, R., “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
M. Bolós, Llorens-Martín, M., Jurado-Arjona, J., Hernández, F., Rábano, A., and Avila, J., “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
V. Bonet-Costa, Herranz-Pérez, V., Blanco-Gandía, M. C., Mas-Bargues, C., Inglés, M., Garcia-Tarraga, P., Rodriguez-Arias, M., Miñarro, J., Borras, C., Garcia-Verdugo, J. Manuel, and Viña, J., “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
B. O. A. Botchway, Moore, M. K., Akinleye, F. O., Iyer, I. C., and Fang, M., “Nutrition: Review on the Possible Treatment for Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 867-883, 2018.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F., “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
M. A. Burguillos, Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., and Joseph, B., “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.

Pages